Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Plönes, Till ^a   Krohn, Alexander ^a   Burger, Meike ^a   Veelken, Hendrik ^b   Passlick, Bernward ^a   Müller Quernheim, Joachim ^a   Zissel, Gernot ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 2;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CHEMOKINES, CC; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 84864712033     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041746     Document Type: Article

References (39)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10-30.
2. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M,et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie 64: e1-164.
3. Morgensztern D, Ng SH, Gao F, Govindan R, (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5: 29-33.
4. Lorusso G, Ruegg C, (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091-1103.
5. Balkwill F, (2004) Cancer and the chemokine network. Nat Rev Cancer 4: 540-550.
6. Bingle L, Brown NJ, Lewis CE, (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265.
7. Mantovani A, Sica A, (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237.
8. Solinas G, Germano G, Mantovani A, Allavena P, (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065-1073.
9. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer. BMC Cancer 10: 172.
10. Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, et al. (2003) PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 163: 2065-2075.
11. Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, et al. (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103: 33-39.
12. Gunther C, Bello-Fernandez C, Kopp T, Kund J, Carballido-Perrig N, et al. (2005) CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 174: 1723-1728.
13. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, et al. (2009) Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 179: 717-723.
14. Wang Q, Li D, Zhang W, Tang B, Li QQ, et al. (2011) Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers.
15. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, et al. (2002) Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 277: 24584-24593.
16. Leung SY, Yuen ST, Chu KM, Mathy JA, Li R, et al. (2004) Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology 127: 457-469.
17. Chang Y, de Nadai P, Azzaoui I, Morales O, Delhem N, et al. (2007) The chemokine CCL18 generates adaptive regulatory T cells from memory CD4+ T cells of healthy but not allergic subjects. Faseb J 24: 5063-5072.
18. Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, et al. (2011) Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 183: 1187-1192.
19. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, et al. (2010) Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol [Epub ahead of print].
20. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
21. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC, (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28: 5311-5320.
22. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, et al. (2008) Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 44: 191-200.
23. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856.
24. Van den Bossche J, Bogaert P, van Hengel J, Guérin C, Berx G, et al. (2009) Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood 114: 4664-4674.
25. Lin EY, Pollard JW, (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90: 2053-2058.
26. Pollard JW, (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
27. Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, et al. (2003) Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 29: 743-749.
28. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, et al. (2006) A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. Am J Respir Crit Care Med 173: 781-792.
29. Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, et al. (2008) Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol 39: 1751-1755.
30. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, et al. (2009) CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 137: 615-621.
31. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, et al. (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92: 913-920.
32. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, et al. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612.
33. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, et al. (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464.
34. Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, et al. (2011) Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 6: 432-438.
35. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A, (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
36. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
37. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543.
38. Bates GJ, Fox SB, Han C, Launchbury R, Leek RD, et al. (2008) Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res Treat 111: 453-459.
39. Hieshima K, Imai T, Baba M, Shoudai K, Ishizuka K, et al. (1997) A novel human CC chemokine PARC that is most homologous to macrophage- inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 159: 1140-1149.